|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Revance Therapeutics, Inc. (RVNC) |
|
|
$3.65 0.00 (0.00%) as of 4:30 Wed 2/5
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
82,270,000 |
| Market
Cap: |
300.29(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.42 - $6.62 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Revance Therapeutics is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. Co.'s segments are: Product, which refers to the business that includes the research, development and commercialization of its product candidates and the RHA® Collection of dermal fillers; and Service, which refers to the business that includes the development and commercialization of the OPUL™ Relational Commerce Platform and HintMD platform.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
30,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$209,400 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
3,908 |
122,109 |
| Total Sell Value |
$0 |
$0 |
$16,296 |
$2,063,714 |
| Total People Sold |
0 |
0 |
1 |
6 |
| Total Sell Transactions |
0 |
0 |
1 |
10 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Foley Mark J |
President & CEO |
• • – |
2025-02-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(112,619) |
0 |
|
- |
|
| Foley Mark J |
President & CEO |
• • – |
2025-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
84,686 |
84,686 |
|
- |
|
| Nolet Chris |
|
– • – |
2025-02-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(15,000) |
0 |
|
- |
|
| Moxie Dwight |
CLO & GC |
• – – |
2025-02-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(114,104) |
0 |
|
- |
|
| Moxie Dwight |
CLO & GC |
• – – |
2025-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
18,125 |
18,125 |
|
- |
|
| Schilke Tobin |
CFO |
• – – |
2025-02-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(124,438) |
0 |
|
- |
|
| Schilke Tobin |
CFO |
• – – |
2025-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
20,883 |
20,883 |
|
- |
|
| Hollander David |
CMO & Global Therapeutics Lead |
• – – |
2025-02-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(95,212) |
0 |
|
- |
|
| Jordan Erica |
Chief Commercial Officer |
• – – |
2025-02-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(107,942) |
0 |
|
- |
|
| Beraud Jill |
|
– • – |
2025-02-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(15,000) |
0 |
|
- |
|
| Kolaja Carey Oconnor |
|
– • – |
2025-02-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(15,000) |
0 |
|
- |
|
| Coric Vlad |
|
– • – |
2025-02-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(15,000) |
0 |
|
- |
|
| Russell Angus C. |
|
– • – |
2025-02-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(15,000) |
0 |
|
- |
|
| Gangolli Julian S |
|
– • – |
2025-02-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(15,000) |
0 |
|
- |
|
| Ware Olivia C |
|
– • – |
2025-02-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(15,000) |
0 |
|
- |
|
| Foley Mark J |
President & CEO |
• • – |
2025-02-04 |
4 |
D |
$3.65 |
$404,832 |
I/I |
(110,913) |
0 |
|
- |
|
| Foley Mark J |
President & CEO |
• • – |
2025-02-04 |
4 |
D |
$3.65 |
$3,638,813 |
D/D |
(996,935) |
27,933 |
|
- |
|
| Nolet Chris |
|
– • – |
2025-02-04 |
4 |
D |
$3.65 |
$104,412 |
D/D |
(28,606) |
15,000 |
|
- |
|
| Moxie Dwight |
CLO & GC |
• – – |
2025-02-04 |
4 |
D |
$3.65 |
$174,525 |
D/D |
(47,815) |
95,979 |
|
- |
|
| Schilke Tobin |
CFO |
• – – |
2025-02-04 |
4 |
D |
$3.65 |
$357,696 |
D/D |
(97,999) |
103,555 |
|
- |
|
| Hollander David |
CMO & Global Therapeutics Lead |
• – – |
2025-02-04 |
4 |
D |
$3.65 |
$35,525 |
D/D |
(9,733) |
95,212 |
|
- |
|
| Jordan Erica |
Chief Commercial Officer |
• – – |
2025-02-04 |
4 |
D |
$3.65 |
$25,265 |
D/D |
(6,922) |
107,942 |
|
- |
|
| Beraud Jill |
|
– • – |
2025-02-04 |
4 |
D |
$3.65 |
$104,412 |
D/D |
(28,606) |
15,000 |
|
- |
|
| Kolaja Carey Oconnor |
|
– • – |
2025-02-04 |
4 |
D |
$3.65 |
$60,448 |
D/D |
(16,561) |
15,000 |
|
- |
|
| Coric Vlad |
|
– • – |
2025-02-04 |
4 |
D |
$3.65 |
$21,112 |
D/D |
(5,784) |
15,000 |
|
- |
|
384 Records found
|
|
Page 1 of 16 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
